Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arzneiwerk AG VIDALTS:0NKY 40 EV-to-FCF is -2.11 as of Aug. 31, 2026. GuruFocus rates LTS:0NKY with a GF Score™ of 40/100. The stock has 7 warning signs investors should review. Among 69 Medical Distribution companies, Arzneiwerk AG VIDA ranks worse than 1449273.91% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Arzneiwerk AG VIDA's Enterprise Value is €1.25 Mil.
Arzneiwerk AG VIDA's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.59 Mil. Therefore, Arzneiwerk AG VIDA's EV-to-FCF for today is -2.11.
The historical rank and industry rank for Arzneiwerk AG VIDA's EV-to-FCF or its related term are showing as below:
LTS:0NKY'
s EV-to-FCF Range Over the Past 10 Years
Min: -131.58 Med: -3.99 Max: 1173.4
Current: -2.11
During the past 13 years, the highest EV-to-FCF of Arzneiwerk AG VIDA was 1173.40. The lowest was -131.58. And the median was -3.99.
LTS:0NKY's EV-to-FCF is ranked worse than 100% of 69
companies
in the Medical Distribution industry
Industry Median: 17.76
vs LTS:0NKY: -2.11
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Arzneiwerk AG VIDA (LTS:0NKY) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Arzneiwerk AG VIDA's PE Ratio (TTM) for today is calculated as:
Arzneiwerk AG VIDA's share price for today is €0.505.
Arzneiwerk AG VIDA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.075.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Arzneiwerk AG VIDA EV-to-FCF Related Terms
Arzneiwerk AG VIDA EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Arzneiwerk AG VIDA's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Arzneiwerk AG VIDA's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arzneiwerk AG VIDA EV-to-FCF vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Arzneiwerk AG VIDA's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Arzneiwerk AG VIDA's EV-to-FCF falls into.
Arzneiwerk AG VIDA's current Enterprise Value is €1.25 Mil.
Arzneiwerk AG VIDA's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.59 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arzneiwerk AG VIDA (LTS:0NKY) has a EV-to-FCF of -2.11 as of Aug. 31, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Arzneiwerk AG VIDA and its competitors. According to the industry distribution chart, Arzneiwerk AG VIDA ranks #999999 out of 69 companies in the Medical Distribution industry.
Is Arzneiwerk AG VIDA's EV-to-FCF too high?
Arzneiwerk AG VIDA's current EV-to-FCF is -2.11. Based on the distribution chart, Arzneiwerk AG VIDA ranks #999999 out of 69 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Arzneiwerk AG VIDA has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Arzneiwerk AG VIDA's EV-to-FCF compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Arzneiwerk AG VIDA ranks #999999 out of 69 companies for EV-to-FCF. This places Arzneiwerk AG VIDA in the lower half of its industry. The industry median EV-to-FCF is 17.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Distribution company?
The median EV-to-FCF among Medical Distribution companies is 17.76, based on 69 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Arzneiwerk AG VIDA and its competitors. For the Medical Distribution industry, the median EV-to-FCF is 17.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arzneiwerk AG VIDA's current EV-to-FCF is -2.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arzneiwerk AG VIDA stock overvalued right now?
Arzneiwerk AG VIDA (LTS:0NKY) has a current EV-to-FCF of -2.11. The current EV-to-FCF is -2.11. Arzneiwerk AG VIDA's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Arzneiwerk AG VIDA (LTS:0NKY), the current EV-to-FCF is -2.11 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Arzneiwerk AG VIDA is active in the pharmaceutical industry. The Pharma segment combines pharmaceutical supply with a focus on digitalization and process optimization along the pharmaceutical value chains and the management of large data volumes in the pharmaceutical industry. The company focuses on the growth area of specialty pharma in Germany and Europe.
40GF Score
Get the complete analysis for LTS:0NKY
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0NKY has been successfully added to your 
